fbpx
June 6, 2022

Methotrexate’s First Evidence of Disease Modification in Pre-RA Methotrexate’s First Evidence of Disease Modification in Pre-RA

COPENHAGEN — Temporary methotrexate in clinically suspected arthralgia delays but does not prevent clinical arthritis development; however, it does lead to sustained reduction of disease burden and […]
June 6, 2022

Crohn’s Disease Biomarker Appears Years Ahead of Diagnosis Crohn’s Disease Biomarker Appears Years Ahead of Diagnosis

Anti–granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies predict complicated Crohn’s disease (CD) years before signs or symptoms of the disease appear, according to new data. A study of […]
June 6, 2022

‘Remission Is Possible’ for Patients With Type 2 Diabetes ‘Remission Is Possible’ for Patients With Type 2 Diabetes

A novel approach that involves sensors, artificial intelligence, and real-time individualized lifestyle guidance from an app and live coaches led to a high rate of remission […]
June 6, 2022

FDA Advisers Consider Novavax COVID-19 Vaccine This Week FDA Advisers Consider Novavax COVID-19 Vaccine This Week

The FDA’s vaccine advisors are scheduled to meet on Tuesday to consider authorizing the Novavax COVID-19 vaccine. The committee will vote on whether the benefits of […]
June 6, 2022

Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’ Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’

CHICAGO — Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, benefited from the anti-HER2 antibody drug conjugate trastuzumab deruxtecan. The therapy […]
June 6, 2022

Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma

A weekly subcutaneous dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from 165 patients in […]
June 6, 2022

Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change? Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change?

When physicians lament they feel burned out at work, what exactly do they mean? Here’s how one doctor describes conditions that lead to burnout: “I barely […]
June 6, 2022

EULAR RA Recommendations: Start Methotrexate, Steroids First EULAR RA Recommendations: Start Methotrexate, Steroids First

COPENHAGEN – New recommendations for the management of rheumatoid arthritis from the European Alliance of Associations for Rheumatology suggest starting short-term methotrexate and glucocorticoids when starting or […]
June 6, 2022

Sacituzumab a ‘Step Forward’ in Breast Cancer Unmet Need Sacituzumab a ‘Step Forward’ in Breast Cancer Unmet Need

An antibody drug conjugate that targets a cell-surface antigen found on most breast and bladder cancers demonstrated improved progression-free survival over standard chemotherapy in patients with […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0